MEI Pharma, Inc. (MEIP)

NASDAQ: MEIP · IEX Real-Time Price · USD
4.000
+0.050 (1.27%)
At close: Mar 28, 2024, 4:00 PM
4.070
+0.070 (1.75%)
After-hours: Mar 28, 2024, 4:30 PM EDT

Total Valuation

MEI Pharma has a market cap or net worth of $26.65 million. The enterprise value is -$20.80 million.

Market Cap 26.65M
Enterprise Value -20.80M

Important Dates

The next estimated earnings date is Thursday, May 9, 2024, after market close.

Earnings Date May 9, 2024
Ex-Dividend Date n/a

Share Statistics

MEI Pharma has 6.66 million shares outstanding.

Shares Outstanding 6.66M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 0.55%
Owned by Institutions (%) 47.60%
Float 4.94M

Valuation Ratios

The trailing PE ratio is 1.35.

PE Ratio 1.35
Forward PE n/a
PS Ratio 0.37
Forward PS 298.62
PB Ratio 0.45
P/FCF Ratio n/a
PEG Ratio 20.60
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.23, with a Debt / Equity ratio of 0.20.

Current Ratio 8.23
Quick Ratio n/a
Debt / Equity 0.20
Debt / EBITDA 0.55
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is 39.70% and return on invested capital (ROIC) is 22.21%.

Return on Equity (ROE) 39.70%
Return on Assets (ROA) 18.30%
Return on Capital (ROIC) 22.21%
Revenue Per Employee $1.58M
Profits Per Employee $431,391
Employee Count 46
Asset Turnover 0.67
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -11.97% in the last 52 weeks. The beta is 0.65, so MEI Pharma's price volatility has been lower than the market average.

Beta (1Y) 0.65
52-Week Price Change -11.97%
50-Day Moving Average 4.27
200-Day Moving Average 5.99
Relative Strength Index (RSI) 48.91
Average Volume (30 Days) 24,349

Short Selling Information

The latest short interest is 9,096, so 0.14% of the outstanding shares have been sold short.

Short Interest 9,096
Short Previous Month 12,480
Short % of Shares Out 0.14%
Short % of Float 0.18%
Short Ratio (days to cover) 0.32

Income Statement

In the last 12 months, MEI Pharma had revenue of $72.65 million and earned $19.84 million in profits. Earnings per share was $2.97.

Revenue 72.65M
Gross Profit 72.65M
Operating Income 15.88M
Pretax Income 19.84M
Net Income 19.84M
EBITDA 21.69M
EBIT 19.84M
Earnings Per Share (EPS) $2.97
Full Income Statement

Balance Sheet

The company has $59.48 million in cash and $12.03 million in debt, giving a net cash position of $47.45 million or $7.12 per share.

Cash & Cash Equivalents 59.48M
Total Debt 12.03M
Net Cash 47.45M
Net Cash Per Share $7.12
Equity / Book Value 59.49M
Book Value Per Share 8.93
Working Capital 58.13M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$52.98 million and capital expenditures -$55,000, giving a free cash flow of -$53.03 million.

Operating Cash Flow -52.98M
Capital Expenditures -55,000
Free Cash Flow -53.03M
FCF Per Share -$7.96
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of 21.86% and 27.32%.

Gross Margin 100.00%
Operating Margin 21.86%
Pretax Margin 27.32%
Profit Margin 27.32%
EBITDA Margin 29.85%
EBIT Margin 27.32%
FCF Margin -73.00%

Dividends & Yields

MEI Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield 74.46%
FCF Yield -198.99%
Dividend Details

Analyst Forecast

The average price target for MEI Pharma is $43.50, which is 987.50% higher than the current price. The consensus rating is "Buy".

Price Target $43.50
Price Target Difference 987.50%
Analyst Consensus Buy
Analyst Count 2
Revenue Growth Forecast (5Y) -12.18%
EPS Growth Forecast (5Y) -27.63%
Stock Forecasts

Stock Splits

The last stock split was on April 17, 2023. It was a reverse split with a ratio of 1:20.

Last Split Date Apr 17, 2023
Split Type Reverse
Split Ratio 1:20

Scores

MEI Pharma has an Altman Z-Score of -2.94 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -2.94
Piotroski F-Score 5